pyrazines has been researched along with formazans in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kotoula, V; McMillin, D; Miller, JW; Mitsiades, CS; Mitsiades, N; Negri, J; Poulaki, V | 1 |
| Kim, SG; Shin, SM | 1 |
| Guo, S; Li, X; Qu, F; Tian, C; Xia, B; Yu, Y; Zhang, L; Zhang, Y | 1 |
3 other study(ies) available for pyrazines and formazans
| Article | Year |
|---|---|
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Flow Cytometry; Formazans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Indicators and Reagents; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines; Retinal Neoplasms; Retinoblastoma; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Tumor Cells, Cultured; Up-Regulation | 2007 |
Inhibition of arachidonic acid and iron-induced mitochondrial dysfunction and apoptosis by oltipraz and novel 1,2-dithiole-3-thione congeners.
Topics: Apoptosis; Arachidonic Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Formazans; Humans; In Situ Nick-End Labeling; Iron; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Pyrazines; Reactive Oxygen Species; Tetrazolium Salts; Thiones; Thiophenes; Time Factors | 2009 |
[Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Formazans; Humans; Lymphoma, Mantle-Cell; MAP Kinase Signaling System; Neoplasm Proteins; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Purines; Pyrazines; Quinazolinones; Signal Transduction; Software; Tetrazolium Salts | 2015 |